Discussion Topic – PTSD.
“PTSD has a lifetime prevalence that is close to 10% and shares neurobiological features with anxiety disorders. Anxiety disorders are the most common class of mental conditions and are highly comorbid with other disorders; treatment considerations typically include cognitive-behavioral therapy and pharmacologic intervention” (Williamson, Jaffee, & Jorge, 2021, p. 1763).
Reference
Williamson, J. B., Jaffee, M. S., & Jorge, R. E. (2021). Posttraumatic Stress Disorder and Anxiety-Related Conditions. Continuum (Minneapolis, Minn.), 27(6), 1738–1763.
Respond to the following in a minimum of 550 words:
In this week’s discussion you will read a systematic review concerning the evidence for physical interventions for the treatment of trauma and stressor-related disorders.
The Merit-based Incentive Payment System (MIPS) is part of the Centers for Medicaid and Medicare Services’ (CMS’s) efforts to improve care to and outcomes for Medicare recipients (CMS, 2022). Based on performance on identified metrics, participants in MIPS can earn adjustments up (or neutral or down) in reimbursement for Medicare Part B services.
Even though not all patients are covered by Medicare, CMS metrics are often used to demonstrate quality care. One of the 2021 recommended metrics is “Posttraumatic Stress Disorder (PTSD) Outcome Assessment for Adults and Children,” ID number MBHR7. Specifically, this metric will measure:
The percentage of patients with a history of a traumatic event (i.e., an experience that was unusually or especially frightening, horrible, or traumatic) who report symptoms consistent with PTSD for at least one month following the traumatic event and with documentation of a standardized symptom monitor (PCL-5 for adults, CATS for child/adolescent) and demonstrated a response to treatment at six months (+/- 120 days) after the index visit. (Qualified Clinical Data Registry (QCDR, 2021). Note: This is a block quote.
Read the following article:
Greene, T., El-Leithy, S., Billings, J., Albert, I., Birch, J., Campbell, M., Ehntholt, K., Fortune, L., Gilbert, N., Grey, N., Hana, L., Kennerley, H., Lee, D., Lunn, S., Murphy, D., Robertson, M., Wade, D., Brewin, C. R., & Bloomfield, M. A. P. (2022). Anticipating PTSD in severe COVID survivors: the case for screen-and-treat. European Journal of Psychotraumatology, 13(1), 1959707.
Locate 1 of the PTSD screening instruments described in the CMS metric:
PCL-5
CATS
Discuss the following:
Given your personal or professional experience with COVID patients and referencing your reading this week, how difficult will it be to administer one of the above PTSD tools in an inpatient setting, in a follow-up primary care setting to follow at-risk patients, and/or those diagnosed with PTSD? Note: If you do not have personal or professional experience with COVID patients, refer to current literature for context.
What persistent symptoms after severe COVID infection might make screening for PTSD difficult? Locate current (i.e., last 5 years) peer-reviewed literature to support your answers and assertions?
Kaplan & Sadock’s Synopsis of Psychiatry, Ch. 2, 8, 9, 10, and 11
Psychiatric Mental Health Nurse Practitioner Review Manual Ch. 6 and 10
Boland, R., Verdiun, M., & Ruiz, P. (2021). <i>Kaplan & sadock’s synopsis of psychiatry</i> (12th ed.). Wolters Kluwer Health.
PLACE THIS ORDER OR A SIMILAR ORDER WITH NURSING TERM PAPERS TODAY AND GET AN AMAZING DISCOUNT
